Ziopharm Oncology reported $-22670000 in Pre-Tax Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Arena Pharmaceuticals ARNA:US $ -146.1M 27.68M
Biogen BIIB:US $ 814.2M 255M
Curis CRIS:US $ -10.84M 0.91M
Eleven Biotherapeutics EBIO:US $ -25.44M 29.78M
Five Prime Therapeutics FPRX:US $ -20.85M 0M
GlaxoSmithKline GSK:LN 1482M 225M
Immunogen IMGN:US $ -30.74M 3.31M
Intercept Pharmaceuticals ICPT:US $ -11.09M 29.33M
Intrexon XON:US $ -20.12M 1.77M
Johnson & Johnson JNJ:US $ 8058M 282M
Karyopharm Therapeutics KPTI:US $ -53448000 3.82M
Novartis NOVN:VX SF 4424M 620M
Ptc Therapeutics PTCT:US $ -117.88M 10.31M
Regeneron Pharmaceuticals REGN:US $ 3898.3M 2658.7M
Sangamo Biosciences SGMO:US $ -47.15M 1.47M
Tg Therapeutics TGTX:US $ -78.5M 12.13M
Verastem VSTM:US $ -16.9M 1.87M
YTE INCY:US $ 199.6M 31.06M
Ziopharm Oncology ZIOP:US $ -22.67M 1.12M